Aetiological classification and prognosis in patients with heart failure with preserved ejection fraction
© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology..
AIMS: Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome with various causes that may influence prognosis.
METHODS AND RESULTS: We extracted the electronic medical records for 2180 consecutive patients hospitalized between 2016 and 2019 for decompensated heart failure. Using a text mining algorithm looking for a left ventricular ejection fraction ≥50% and plasma brain natriuretic peptide level >100 pg/mL, we identified 928 HFpEF patients. We screened for a prevailing cause of HFpEF according to European guidelines and found that 418 (45.0%) patients had secondary HFpEF due to either myocardial (n = 125, 13.5%) or loading condition abnormalities (n = 293, 31.5%), while the remaining 510 (55.0%) patients had idiopathic HFpEF. We assessed the association between the causes of HFpEF and survival collected up to 31 December 2020 using Cox proportional hazards analysis. Even though patients with idiopathic HFpEF were older, frequently female, and had frequent co-morbidities and a higher crude mortality rate compared with secondary HFpEF patients, their prognosis was similar after adjustment for age and sex. Unsupervised clustering analysis revealed three main phenogroups with different distribution of idiopathic vs. secondary HFpEF. The phenogroup with the highest proportion of idiopathic HFpEF (69%) had (i) an excess rate of non-cardiac co-morbidities including chronic obstructive pulmonary disease (31%) or obesity (41%) and (ii) a better prognosis compared with the two other phenogroups enriched with secondary HFpEF.
CONCLUSIONS: Aetiological classification provides clinical and prognostic information and may be useful to better decipher the clinical heterogeneity of HFpEF.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
ESC heart failure - 9(2022), 1 vom: 21. Feb., Seite 519-530 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fayol, Antoine [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aetiologies |
|---|
| Anmerkungen: |
Date Completed 25.03.2022 Date Revised 25.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/ehf2.13717 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333788249 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333788249 | ||
| 003 | DE-627 | ||
| 005 | 20231225222352.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ehf2.13717 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1112.xml |
| 035 | |a (DE-627)NLM333788249 | ||
| 035 | |a (NLM)34841727 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fayol, Antoine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Aetiological classification and prognosis in patients with heart failure with preserved ejection fraction |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2022 | ||
| 500 | |a Date Revised 25.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. | ||
| 520 | |a AIMS: Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome with various causes that may influence prognosis | ||
| 520 | |a METHODS AND RESULTS: We extracted the electronic medical records for 2180 consecutive patients hospitalized between 2016 and 2019 for decompensated heart failure. Using a text mining algorithm looking for a left ventricular ejection fraction ≥50% and plasma brain natriuretic peptide level >100 pg/mL, we identified 928 HFpEF patients. We screened for a prevailing cause of HFpEF according to European guidelines and found that 418 (45.0%) patients had secondary HFpEF due to either myocardial (n = 125, 13.5%) or loading condition abnormalities (n = 293, 31.5%), while the remaining 510 (55.0%) patients had idiopathic HFpEF. We assessed the association between the causes of HFpEF and survival collected up to 31 December 2020 using Cox proportional hazards analysis. Even though patients with idiopathic HFpEF were older, frequently female, and had frequent co-morbidities and a higher crude mortality rate compared with secondary HFpEF patients, their prognosis was similar after adjustment for age and sex. Unsupervised clustering analysis revealed three main phenogroups with different distribution of idiopathic vs. secondary HFpEF. The phenogroup with the highest proportion of idiopathic HFpEF (69%) had (i) an excess rate of non-cardiac co-morbidities including chronic obstructive pulmonary disease (31%) or obesity (41%) and (ii) a better prognosis compared with the two other phenogroups enriched with secondary HFpEF | ||
| 520 | |a CONCLUSIONS: Aetiological classification provides clinical and prognostic information and may be useful to better decipher the clinical heterogeneity of HFpEF | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Aetiologies | |
| 650 | 4 | |a Classification | |
| 650 | 4 | |a Heart failure with preserved ejection faction | |
| 650 | 4 | |a Prognosis | |
| 700 | 1 | |a Wack, Maxime |e verfasserin |4 aut | |
| 700 | 1 | |a Livrozet, Marine |e verfasserin |4 aut | |
| 700 | 1 | |a Carves, Jean-Baptiste |e verfasserin |4 aut | |
| 700 | 1 | |a Domengé, Orianne |e verfasserin |4 aut | |
| 700 | 1 | |a Vermersch, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Mirabel, Mariana |e verfasserin |4 aut | |
| 700 | 1 | |a Karras, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Le Guen, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Blanchard, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Azizi, Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Amar, Laurence |e verfasserin |4 aut | |
| 700 | 1 | |a Bories, Marie-Cécile |e verfasserin |4 aut | |
| 700 | 1 | |a Mousseaux, Elie |e verfasserin |4 aut | |
| 700 | 1 | |a Carette, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Puymirat, Etienne |e verfasserin |4 aut | |
| 700 | 1 | |a Hagège, Albert |e verfasserin |4 aut | |
| 700 | 1 | |a Jannot, Anne-Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Hulot, Jean-Sébastien |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ESC heart failure |d 2014 |g 9(2022), 1 vom: 21. Feb., Seite 519-530 |w (DE-627)NLM261791397 |x 2055-5822 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2022 |g number:1 |g day:21 |g month:02 |g pages:519-530 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ehf2.13717 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2022 |e 1 |b 21 |c 02 |h 519-530 | ||